Literature DB >> 9491281

Reduced gonadal toxicity after i.v. cyclophosphamide administration in patients with nonmalignant diseases.

M Haubitz1, C Ehlerding, K Kamino, K M Koch, R Brunkhorst.   

Abstract

BACKGROUND: Cyclophosphamide has been used increasingly to treat patients with nonmalignant diseases like primary glomerulonephritis and systemic vasculitis. Thus long-term side effects like gonadal toxicity have become an important issue. Monthly i.v. cyclophosphamide pulse administration leads to a reduction in total dose of 60% compared to daily oral treatment which would be favorable for i.v. therapy. However, the risk of increased germinal damage due to higher peak levels had to be excluded.
METHODS: Gonadal toxicity after different modes of cyclophosphamide administration was investigated in men with vasculitis or minimal change glomerulonephritis by measurement of FSH (follicle-stimulating hormone) plasma levels, as well as in Lewis rats by the investigation of testis histology and number of foetuses after mating with healthy female rats.
RESULTS: FSH plasma levels after 3 months of treatment were significantly higher in men receiving daily oral cyclophosphamide (28.7 +/- 34 IU/l) compared to i.v. pulse administration (9.5 +/- 5.1 IU/l; p < 0.01) indicating a higher gonadal toxicity after oral treatment. In Lewis rats daily oral gavage led to a significantly reduced number of foetuses and changes in testis histology compared to pulse administration.
CONCLUSION: As pulse administration of cyclophosphamide led to a significantly reduced gonadal toxicity compared to oral treatment this administration should be preferred, provided that an equal disease control and relapse rate is achieved.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9491281

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  7 in total

Review 1.  Clinical management and treatment of vasculitis.

Authors:  D Jayne
Journal:  Springer Semin Immunopathol       Date:  2001

Review 2.  The use of immunosuppressive and cytotoxic drugs in non-malignant disease.

Authors:  P A Brogan; M J Dillon
Journal:  Arch Dis Child       Date:  2000-09       Impact factor: 3.791

Review 3.  French recommendations for the management of systemic necrotizing vasculitides (polyarteritis nodosa and ANCA-associated vasculitides).

Authors:  Benjamin Terrier; Raphaël Darbon; Cécile-Audrey Durel; Eric Hachulla; Alexandre Karras; Hélène Maillard; Thomas Papo; Xavier Puechal; Grégory Pugnet; Thomas Quemeneur; Maxime Samson; Camille Taille; Loïc Guillevin
Journal:  Orphanet J Rare Dis       Date:  2020-12-29       Impact factor: 4.123

4.  Myeloperoxidase-specific plasma cell depletion by bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis.

Authors:  Julia Bontscho; Adrian Schreiber; Rudolf A Manz; Wolfgang Schneider; Friedrich C Luft; Ralph Kettritz
Journal:  J Am Soc Nephrol       Date:  2011-01-13       Impact factor: 10.121

5.  Pulse cyclophosphamide therapy in steroid-dependent nephrotic syndrome.

Authors:  Narayan Prasad; Sanjeev Gulati; Raj Kumar Sharma; Uttam Singh; Muffazal Ahmed
Journal:  Pediatr Nephrol       Date:  2004-03-09       Impact factor: 3.714

6.  Systemic and Central Nervous System Vasculitides.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-09       Impact factor: 3.972

7.  Pulse cyclophosphamide therapy for steroid-resistant focal segmental glomerulosclerosis in children.

Authors:  Abdullah A Al Salloum
Journal:  Ann Saudi Med       Date:  2004 Jan-Feb       Impact factor: 1.526

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.